Headquartered in Foster City, California, the company has expanded rapidly over the past two decades, with annual revenues now exceeding $4 billion, operations spanning three continents (North America, Europe and Australia) and a staff of more than 3,000 employees.
Gilead’s primary areas of focus include: antivirals (such as HIV/AIDS and chronic hepatitis), cardiovascular conditions (such as pulmonary arterial hypertension and resistant hypertension) and respiratory diseases (such as influenza and cystic fibrosis).
Our growing pipeline includes novel investigational medications for resistant hypertension, cystic fibrosis, HIV and hepatitis